Healthcare
IRadimed Corporation(IRMD)
Live Price
Offline$92.20
+1.22% today
1Y Change
+52.05%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $1.09B
- Revenue Growth
- +14.4%
- EPS Growth
- +16.4%
- Dividend Yield
- 1.4%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IRadimed Corporation (IRMD) is a Healthcare stock with a market cap of $1.09B and listed on NASDAQ. The stock last traded around $92.20 and up 52.1% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +14.4%, EPS growth of +16.4%, a dividend yield of 1.4%. What stands out right now is revenue +14.4%, EPS +16.4%, free cash flow -2.5% with operating margin 32.4% and ROIC 21.4%. The dividend is present but secondary, with a yield around 1.4%. Valuation already assumes a fairly strong business story at P/E 46.0 and price/sales 12.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines IRMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14.4% vs +7.6% peer median
Operating Margin
Above sector median
+32.4% vs +19.4% peer median
P/E
Above sector median
46.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +14.4% and EPS at +16.4%, with operating margin around 32.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +1.1% | -0.7% | +5.8% |
2026 Feb 10, 2026 | +10.2% | -2.0% | -3.5% | -4.1% |
2025 Nov 3, 2025 | -2.1% | +3.1% | +2.3% | +9.5% |
Benchmark Edge
IRMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IRMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IRMD Max Drawdown
-20.65%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IRMD and SPY.
Company Overview
IRadimed Corporation
NASDAQ Capital Market
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
- Leadership
- Roger E. Susi
- IPO Date
- Jul 16, 2014
- Employees
- 160
- Street Address
- 1025 Willa Springs Drive
- Mailing
- Winter Springs, FL, 32708
- Region
- Winter Springs, FL, US
- Reporting Currency
- USD
- Investor Line
- 407 677 8022
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 46.0
- EV/EBITDA
- 33.7
- Price/Sales
- 12.6
- Price/Book
- 11.0
Growth
- Revenue
- +14.4%
- EPS
- +16.4%
- Free Cash Flow
- -2.5%
Profitability
- Gross Margin
- 76.8%
- Operating Margin
- 32.4%
- Net Margin
- 27.4%
- ROE
- 24.5%
- ROIC
- 21.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 7.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.